Atracurium

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Atracurium
Accession Number
DB13295
Description
Not Available
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Synonyms
Not Available

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Atracurium.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Atracurium.
AcetyldigitoxinThe risk or severity of Cardiac Arrhythmia can be increased when Atracurium is combined with Acetyldigitoxin.
AclidiniumAtracurium may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Atracurium.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Atracurium.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Atracurium.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Atracurium.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Atracurium.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Atracurium.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Categories

ATC Codes
M03AC04 — Atracurium
Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
2GQ1IRY63P
CAS number
64228-79-1
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

References

General References
Not Available
RxNav
1218
Wikipedia
Atracurium

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticAtracurium / Cefazolin / Morphine / Nadroparin / Obese1
4CompletedPreventionKidney Diseases / Prostate Hypertrophy1
4CompletedSupportive CarePost Operative Nausea and Vomiting (PONV) / Postoperative pain1
4CompletedSupportive CareQuality of Ocular Akinesia (Onset and Duration)1
4CompletedTreatmentNeuromuscular Blockade / Regional Anesthesia1
4CompletedTreatmentTracheal Intubation1
4Unknown StatusOtherPatients Undergoing Laparoscopic Surgery1
4Unknown StatusTreatmentAnaesthesia therapy1
4Unknown StatusTreatmentMyoclonus1
3CompletedDiagnosticPostoperative pain1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solution25 MG/2.5ML
Injection, solution50 MG/5ML
SolutionIntravenous50 mg
InjectionIntravenous25 mg/2.5ml
InjectionIntravenous50 mg/5ml
Injection
Injection, solutionIntravenous25 MG/2.5ML
Injection, solutionIntravenous50 MG/5ML
Injection25 mg/2.5ml
Injection50 mg/5ml
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on June 23, 2017 14:39 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates